All In Biotech

Drug Trial Radar · NCT02291861

Addressing Involuntary Movements in Tardive Dyskinesia

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 298 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

298

Actual

Start

Oct 31, 2014

Primary completion

Aug 19, 2016

Study completion Aug 19, 2016

Sponsor

Lead sponsor
Auspex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Conditions

  • Tardive Dyskinesia

Interventions

  • SD-809Drug

    SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.

  • PlaceboDrug

    Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)Time frame: Day 0 (Baseline), Weeks 2, 4, 8 and 12

Locations

106 sites in 6 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 145

    Tuscaloosa, Alabama

  • Teva Investigational Site 107

    Anaheim, California

  • Teva Investigational Site 108

    Anaheim, California

  • Teva Investigational Site 123

    Glendale, California

  • Teva Investigational Site 177

    Imperial, California

  • Teva Investigational Site 160

    Irvine, California

  • Teva Investigational Site 106

    Irvine, California

  • Teva Investigational Site 176

    Loma Linda, California

  • Teva Investigational Site 121

    Los Angeles, California

  • Teva Investigational Site 147

    Los Angeles, California

  • Teva Investigational Site 174

    Norwalk, California

  • Teva Investigational Site 170

    Oceanside, California

  • Teva Investigational Site 102

    Orange, California

  • Teva Investigational Site 104

    San Bernardino, California

  • Teva Investigational Site 110

    San Diego, California

  • Teva Investigational Site 169

    San Rafael, California

  • Teva Investigational Site 129

    Englewood, Colorado

  • Teva Investigational Site 139

    New Haven, Connecticut

  • Teva Investigational Site 156

    Washington D.C., District of Columbia

  • Teva Investigational Site 157

    Boca Raton, Florida

  • Teva Investigational Site 117

    Gainesville, Florida

  • Teva Investigational Site 150

    Lake City, Florida

  • Teva Investigational Site 153

    Miami, Florida

  • Teva Investigational Site 162

    Miami, Florida

  • Teva Investigational Site 112

    Orlando, Florida

  • Teva Investigational Site 144

    Port Charlotte, Florida

  • Teva Investigational Site 155

    Augusta, Georgia

  • Teva Investigational Site 165

    Decatur, Georgia

  • Teva Investigational Site 131

    Chicago, Illinois

  • Teva Investigational Site 113

    Chicago, Illinois

  • Teva Investigational Site 164

    Kansas City, Kansas

  • Teva Investigational Site 154

    Baltimore, Maryland

  • Teva Investigational Site 101

    Glen Burnie, Maryland

  • Teva Investigational Site 135

    Boston, Massachusetts

  • Teva Investigational Site 118

    Creve Coeur, Missouri

  • Teva Investigational Site 142

    Kansas City, Missouri

  • Teva Investigational Site 175

    St Louis, Missouri

  • Teva Investigational Site 161

    St Louis, Missouri

  • Teva Investigational Site 178

    Lincoln, Nebraska

  • Teva Investigational Site 128

    Albuquerque, New Mexico

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.